{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T17:35:48Z","timestamp":1780335348962,"version":"3.54.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["transplantation-proceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.transproceed.2014.05.087","type":"journal-article","created":{"date-parts":[[2014,12,9]],"date-time":"2014-12-09T15:02:46Z","timestamp":1418137366000},"page":"3375-3382","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["A Randomized Trial of Everolimus and Low-dose Cyclosporine in Renal Transplantation: With or Without Steroids?"],"prefix":"10.1016","volume":"46","author":[{"given":"C.","family":"Ponticelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Carmellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Tisone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sandrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Segoloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Rigotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Colussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Stefoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2014.05.087_bib1","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/S0041-1345(98)00588-0","article-title":"The in\u00a0vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferation","volume":"30","author":"Bohler","year":"1998","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2014.05.087_bib2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2337\/diabetes.55.01.06.db05-0613","article-title":"Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance","volume":"55","author":"Battaglia","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.transproceed.2014.05.087_bib3","doi-asserted-by":"crossref","first-page":"7018","DOI":"10.4049\/jimmunol.178.11.7018","article-title":"Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance","volume":"178","author":"Turnquist","year":"2007","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.transproceed.2014.05.087_bib4","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJMoa022171","article-title":"Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients","volume":"349","author":"Eisen","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.transproceed.2014.05.087_bib5","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.healun.2007.03.005","article-title":"Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis","volume":"26","author":"Vigano","year":"2007","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"Suppl 3","key":"10.1016\/j.transproceed.2014.05.087_bib6","doi-asserted-by":"crossref","first-page":"iii9","DOI":"10.1093\/ndt\/gfl295","article-title":"Long-term cardiovascular risk in transplantation\u2014insights from the use of everolimus in heart transplantation","volume":"21","author":"Eisen","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transproceed.2014.05.087_bib7","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1124\/jpet.108.144147","article-title":"Everolimus inhibits monocyte\/macrophage migration in\u00a0vitro and their accumulation in carotid lesions of cholesterol-fed rabbits","volume":"328","author":"Baetta","year":"2009","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.transproceed.2014.05.087_bib8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.atherosclerosis.2007.09.019","article-title":"Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR-\/- mice despite severe hypercholesterolemia","volume":"198","author":"Mueller","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.transproceed.2014.05.087_bib9","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1097\/01.tp.0000219703.39149.85","article-title":"Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials","volume":"81","author":"Webster","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2014.05.087_bib10","doi-asserted-by":"crossref","first-page":"6022","DOI":"10.1128\/JVI.75.13.6022-6032.2001","article-title":"Human cytomegalovirus up-regulates the phosphatidylinositol 3-kinase (PI3-K) pathway: inhibition of PI3-K activity inhibits viral replication and virus-induced signaling","volume":"75","author":"Johnson","year":"2001","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.transproceed.2014.05.087_bib11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1189\/jlb.1203621","article-title":"HCMV activates PI(3)K in monocytes and promotes monocyte motility and transendothelial migration in a PI(3)K-dependent manner","volume":"76","author":"Smith","year":"2004","journal-title":"J\u00a0Leukoc Biol"},{"key":"10.1016\/j.transproceed.2014.05.087_bib12","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/TP.0b013e318276a1ef","article-title":"Everolimus-treated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporine- or mycophenolate-treated patients","volume":"95","author":"Havenith","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2014.05.087_bib13","first-page":"762","article-title":"The pleiotropic effects of mTor inhibitors","volume":"17","author":"Ponticelli","year":"2004","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.transproceed.2014.05.087_bib14","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/01.TP.0000184006.43152.8D","article-title":"Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies","volume":"80","author":"Kauffman","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2014.05.087_bib15","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ejca.2012.09.013","article-title":"Risk of de novo cancers after transplantation: results from a cohort of 7217 kidney transplant recipients, Italy 1997-2009","volume":"49","author":"Piselli","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.transproceed.2014.05.087_bib16","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1016\/j.transproceed.2006.10.092","article-title":"Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus","volume":"38","author":"Kovarik","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2014.05.087_bib17","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1097\/01.TP.0000140486.97461.49","article-title":"Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study","volume":"78","author":"Nashan","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2014.05.087_bib18","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1097\/TP.0b013e318216c1db","article-title":"Everolimus and minimization of cyclosporine in renal transplantation: 24-month follow-up of the EVEREST study","volume":"91","author":"Ponticelli","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2014.05.087_bib19","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1681\/ASN.V12102163","article-title":"Long-term results of a randomized study comparing three immunosuppressive schedules with cyclosporine in cadaveric kidney transplantation","volume":"12","author":"Montagnino","year":"2001","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.transproceed.2014.05.087_bib20","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1097\/00007890-199910270-00007","article-title":"A\u00a0phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients","volume":"68","author":"Kahan","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2014.05.087_bib21","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.transproceed.2010.03.084","article-title":"Once-a-day administration of everolimus, cyclosporine, and steroid after renal transplantation: a review of the rationale","volume":"42","author":"Corbetta","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2014.05.087_bib22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.transproceed.2014.05.087_bib23","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1097\/00007890-199506270-00007","article-title":"Predicting glomerular filtration rate after kidney transplantation","volume":"59","author":"Nankivell","year":"1995","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2014.05.087_bib24","first-page":"S11","article-title":"KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease","volume":"47","author":"KDOQI, National Kidney Foundation","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.transproceed.2014.05.087_bib25","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1046\/j.1523-1755.1999.00299.x","article-title":"The Banff 97 working classification of renal allograft pathology","volume":"55","author":"Racusen","year":"1999","journal-title":"Kidney Int"},{"key":"10.1016\/j.transproceed.2014.05.087_bib26","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0195-668X(03)00114-3","article-title":"Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project","volume":"24","author":"Conroy","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.transproceed.2014.05.087_bib27","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/ndt\/gfr374","article-title":"Very early steroid withdrawal or complete avoidance for kidney transplant recipients: a systematic review","volume":"27","author":"Pascual","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transproceed.2014.05.087_bib28","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1600-6143.2004.00765.x","article-title":"Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients","volume":"5","author":"Opelz","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2014.05.087_bib29","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1399-0012.2006.00579.x","article-title":"Steroid-free immunosuppression regime reduces both long-term cardiovascular morbidity and patient mortality in renal transplant recipients","volume":"20","author":"Sandrini","year":"2006","journal-title":"Clin Transplant"},{"key":"10.1016\/j.transproceed.2014.05.087_bib30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/TP.0b013e318160254f","article-title":"Risk factors for cardiovascular events after successful renal transplantation","volume":"85","author":"Vanrenterghem","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2014.05.087_bib31","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1111\/ajt.12313","article-title":"Association between steroid dosage and death with a functioning graft after kidney transplantation","volume":"13","author":"Opelz","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2014.05.087_bib32","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/ndt\/gfm621","article-title":"A\u00a0randomized exploratory trial of steroid avoidance in renal transplant patients treated with everolimus and low-dose cyclosporine","volume":"23","author":"Montagnino","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transproceed.2014.05.087_bib33","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/TP.0b013e3182295bed","article-title":"Pediatric kidney transplantation followed by de novo therapy with everolimus, low-dose cyclosporine A, and steroid elimination: 3-year data","volume":"92","author":"Pape","year":"2011","journal-title":"Transplantation"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004113451400921X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004113451400921X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,24]],"date-time":"2022-04-24T03:28:14Z","timestamp":1650770894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004113451400921X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S004113451400921X"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2014.05.087","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Randomized Trial of Everolimus and Low-dose Cyclosporine in Renal Transplantation: With or Without Steroids?","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2014.05.087","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}